Academia Sinica Life Science Library -- Research Findings

:::

Research Findings

Inst. of Biomedical Sciences - 羅傅倫 Roffler, Steve R.

Journal 177

Chen E, Chen BM, Su YC, Chang YC, Cheng TL, Barenholz Y*, (Roffler SR*). Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex. ACS nano. , 2020-07. [JCR]　[WOS]
Meng JL, Dong ZX, Chen YR, Lin MH, Liu YC, Roffler SR, Lin WW, Chang CY, Tzou SC, Cheng TL, Huang HC, Li ZQ, Lin YC, Su YC. pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma. ACS NANO. 19(1), 307-321, 2025-01.
Chen Bing-Mae, Chen Even, Lin Yi-Chen, Tran Trieu Thi My, Turjeman Keren, Yang Shih-Hung, Cheng Tian-Lu, Barenholz Yechezkel, Roffler Steve R. Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies. ACS Nano. epub ahead of print, NA-NA, 2024-08. [JCR]　[WOS]
Tseng Yi-Han, Lin Hsuan-Pei, Lin Sung-Yao, Chen Bing-Mae, Vo Thanh Nguyet Nguyen, Yang Shih-Hung, Lin Yi-Chen, Prijovic Zeljko, Czosseck Andreas, Leu Yu-Lin, Roffler Steve R. Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs. Journal of Controlled Release. 369, 179-198, 2024-05. [JCR]　[WOS]
Liu YL, Liao TY, Ho KW, Liu ES, Huang BC, Hong ST, Hsieh YC, Chang MS, Wu BT, Chen FM, Roffler SR, Chen CY, Yang YC, Cheng TL. Impact of Pre-existing Anti-polyethylene Glycol Antibodies on the Pharmacokinetics and Efficacy of a COVID-19 mRNA Vaccine (Comirnaty) In Vivo. Biomaterials research. 28, 0112, 2024.
Tran Trieu TM, Roffler Steve R. Interactions between nanoparticle corona proteins and the immune system. Current Opinion in Biotechnology. 84, 103010, 2023-12. [JCR]　[WOS]
Chen Huei-Jen, Cheng Yi-An, Chen Yu-Tung, Li Chia-Ching, Huang Bo-Cheng, Hong Shih-Ting, Chen I.-Ju, Ho Kai-Wen, Chen Chiao-Yun, Chen Fang-Ming, Wang Jaw-Yuan, Roffler Steve R., Cheng Tian-Lu, Wu Dung-Ho. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20). Cancer Nanotechnology. 14(1), 78, 2023-10. [JCR]　[WOS]
Beishenaliev Adilet, Loke Yean Leng, Goh Sook Jing, Geo Hui Nee, Mugila Malar, Misran Misni, Chung Lip Yong, Kiew Lik Voon, Roffler Steve, Teo Yin Yin. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. Journal of Controlled Release. 359, 268-286, 2023-07. [JCR]　[WOS]
Chen Wei-An, Chang Deng-Yuan, Chen Bing-Mae, Lin Yi-Chen, Barenholz Yechezekel, Roffler Steve R. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines. ACS Nano. 17(6), 5757-5772, 2023-03. [JCR]　[WOS]
Bavli Yaelle, Chen Bing-Mae, Gross Guy, Hershko Alon, Turjeman Keren, Roffler Steve, Barenholz Yechezkel. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). Journal of Controlled Release. 354, 316-322, 2023-02. [JCR]　[WOS]
Lin YC, Chen BM, Tran TTM, Chang TC, Al-Qaisi TS, Roffler SR*. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. Journal of controlled release : official journal of the Controlled Release Society. 354, 354-367, 2023-01. [JCR]　[WOS]
Burnouf PA, (Roffler SR), Wu CC, Su YC. Glucuronides: From biological waste to bio-nanomedical applications. Journal of controlled release : official journal of the Controlled Release Society. 349, 765-782, 2022-09. [JCR]　[WOS]
Sahoo BK, Lin YC, Tu CF, Lin CC, Liao WJ, Li FA, Li LH, Mou KY, (Roffler SR), Wang SP, Yeh CT, Yao CY, Hou HA, Chou WC, Tien HF, Yang RB*. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia. Haematologica. 10.3324/haematol.2022.281151, x, 2022-08. [JCR]　[WOS]
Nguyen MT, Shih YC, Lin MH, (Roffler SR), Hsiao CY, Cheng TL, Lin WW, Lin EC, Jong YJ, Chang CY, Su YC. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Communications chemistry. 5(1), 88, 2022-08. [JCR]　[WOS]
Lin HJ, Liang TL, Chang YY, Liu DZ, Fan JY, (Roffler SR), Lin SY. Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics. 14(6), 10.3390/pharmaceutic, 2022-07. [JCR]　[WOS]
Kim J, Li C, Wang H, Kaviraj S, Singh S, Savergave L, Raghuwanshi A, Gil S, Germond A, Baldessari A, Chen B, (Roffler S), Fender P, Drescher C, Carter D, Lieber A. Translational development of a tumor junction opening technology. Scientific reports. 12(1), 7753, 2022-05. [JCR]　[WOS]
Cheng WJ, Chuang KH, Lo YJ, Chen M, Chen YJ, (Roffler SR), Ho HO, Lin SY, Sheu MT. Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. Journal of controlled release : official journal of the Controlled Release Society. 344, 235-248, 2022-04. [JCR]　[WOS]
Wang H, Li C, Obadan AO, Frizzell H, Hsiang TY, Gil S, Germond A, Fountain C, Baldessari A, Roffler S, Kiem HP, Fuller DH, Lieber A. In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. Human gene therapy. 33(7-8), 389-403, 2022-04. [JCR]　[WOS]
Cheng KW, Tseng CH, Chen IJ, Huang BC, Liu HJ, Ho KW, Lin WW, Chuang CH, Huang MY, Leu YL, (Roffler SR), Wang JY, Chen YL, Cheng TL. Inhibition of gut microbial beta-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Pharmacological research. 177, 106115, 2022-03. [JCR]　[WOS]
Al-Aghbar MA, Jainarayanan AK, Dustin ML*, (Roffler SR*). The interplay between membrane topology and mechanical forces in regulating T cell receptor activity. Communications biology. 5(1), 40, 2022-01. [JCR]　[WOS]
Chang TC, Chen BM, Wu JY, Cheng TL, (Roffler S*). Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 146, 112502, 2021-12. [JCR]　[WOS]
Chen M, Sheu MT, Cheng TL, (Roffler SR), Lin SY, Chen YJ, Cheng YA, Cheng JJ, Chang HY, Wu TY, Kao AP, Ho YS, Chuang KH. A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor. Biomaterials science. 10(1), 202-215, 2021-11. [JCR]　[WOS]
Chen BM, Cheng TL, (Roffler SR*). Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS nano. 15(9), 14022-14048, 2021-09. [JCR]　[WOS]
Lin HY, Chen CY, Lin TC, Yeh LF, Hsieh WC, Gao S, Burnouf PA, Chen BM, Hsieh TJ, Dashnyam P, Kuo YH, Tu Z, (Roffler SR*), Lin CH*. Entropy-driven binding of gut bacterial beta-glucuronidase inhibitors ameliorates irinotecan-induced toxicity. Communications biology. 4(1), 280, 2021-04. [JCR]　[WOS]
Sylvestre M, Lv S, Yang LF, Luera N, Peeler DJ, Chen BM, (Roffler SR), Pun SH. Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice. Journal of controlled release : official journal of the Controlled Release Society. 331, 142-153, 2021-03. [JCR]　[WOS]
Ho KW, Chen IU, Cheng YA, Liao TY, Liu ES, Chen HJ, Lu YC, Su YC, (Roffler SR), Huang BC, Liu HJ, Huang MY, Chen CY, Cheng TL. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. Journal of nanobiotechnology. 19(1), 16, 2021-01. [JCR]　[WOS]
Fang JL, Beland FA, Tang Y, (Roffler SR). Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma. Toxicology reports. 8, 148-154, 2020-12. [JCR]　[WOS]
Chen I-Ju, Cheng Yi-An, Ho Kai-Wen, Lin Wen-Wei, Cheng Kai-Wen, Lu Yun-Chi, Hsieh Yuan-Chin, Huang Chien-Chiao, Chuang Chih-Hung, Chen Fang-Ming, Su Yu-Cheng, Roffler Steve R., Cheng Tian-Lu. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Acta Biomaterialia. 111, 386-397, 2020-07. [JCR]　[WOS]
Bavli Yaelle, Chen Bing-Mae, Roffler Steve R., Dobrovolskaia Marina A., Elnekave Eldad, Ash Shifra, Barenholz Yechezkel, Turjeman Keren. PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies. Molecules. 25(3) 558, 2020-01. [JCR]　[WOS]
Lee CC, Su YC, Ko TP, Lin LL, Yang CY, Chang SS, (Roffler SR*), Wang AH*. Structural basis of polyethylene glycol recognition by antibody. Journal of biomedical science. 27(1), 12, 2020-01. [JCR]　[WOS]
Chang TC, Chen BM, Lin WW, Yu PH, Chiu YW, Chen YT, Wu JY, Cheng TL, Hwang DY, (Roffler SR*). Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice. Pharmaceutics. 12(1), 2019-12. [JCR]　[WOS]
Cheng YA, Chen IJ, Su YC, Cheng KW, Lu YC, Lin WW, Hsieh YC, Kao CH, Chen FM, Roffler SR, Cheng TL. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. Biomaterials science. 7(8), 3404-3417, 2019-08. [JCR]　[WOS]
Bavli Y, Winkler I, Chen BM, Roffler S, Cohen R, Szebeni J, Barenholz Y. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. Journal of controlled release : official journal of the Controlled Release Society. 306, 138-148, 2019-07. [JCR]　[WOS]
Chen YJ, Chen M, Cheng TL, (Roffler SR), Lin SY, Hsu HL, Wang CH, Chen CY, Kao AP, Cheng JJ, Chuang KH. Simply Mixing Poly Protein G with Detection Antibodies Enhances the Detection Limit and Sensitivity of Immunoassays. Analytical chemistry. 91(13), 8310-8317, 2019-07. [JCR]　[WOS]
TS Al-Qaisi, YC Su, (SR Roffler*). Transient AID expression for in situ mutagenesis with improved cellular fitness. SCIENTIFIC REPORTS. 8, 9413, 2018-06. [JCR]　[WOS]
YC Hsieh, HE Wang, WW Lin, (SR Roffler), TC Cheng, YC Su, Jia-Je Li, CC Chen, CH Huang, BM Chen, JY Wang, TL Cheng*, Fang-Ming Chen*. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. THERANOSTICS. 8(11), 3164-3175, 2018-05. [JCR]　[WOS]
PA Burnouf, YL Leu, YC Su, K Wu, W.C. Lin, (SR Roffler*). Reversible attachment of a glycosidic switch to drugs for secure delivery in nanoliposomes. NATURE COMMUNICATIONS. 9(1), 1843, 2018-05. [JCR]　[WOS]
MA Al-Aghbar, YS Chu, BM Chen, (SR Roffler*). High-Affinity Ligands Can Trigger T Cell Receptor Signaling Without CD45 Segregation. FRONTIERS IN IMMUNOLOGY. 9, 713, 2018-04. [JCR]　[WOS]
Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, Lee MM, Cheng TL, Chen YT*, (Roffler SR*), Wu JY*. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. NATURE COMMUNICATIONS. 8(1), 522, 2017-09. [JCR]　[WOS]
Chen Bing-Mae, Al-Aghbar Mohammad Ameen, Lee Chien-Hsin, Chang Tien-Ching, Su Yu-Cheng, Li Ya-Chen, Chang Shih-En, Chen Chin-Chuan, Chung Tsai-Hua, Liao Yuan-Chun, Lee Chau-Hwang, (Roffler Steve R*). The Affinity of Elongated Membrane-Tethered Ligands Determines Potency of T Cell Receptor Triggering. FRONTIERS IN IMMUNOLOGY. 8, 793, 2017-07. [JCR]　[WOS]
Su YC, Burnouf PA, Chuang KH, Chen BM, Cheng TL, (Roffler SR*). Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. NATURE COMMUNICATIONS. 8, 15507, 2017-06. [JCR]　[WOS]
Lin WW, Cheng YA, Kao CH, (Roffler SR), Lee YC, Chen BM, Hsieh YC, Chen IJ, Huang BC, Wang YT, Tung YC, Huang MY, Chen FM, Cheng TL. Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated Molecules. ANALYTICAL CHEMISTRY. 89(11), 6082-6090, 2017-06. [JCR]　[WOS]
Lin YC, Chao TY, Yeh CT, (Roffler SR), Kannagi R, Yang RB*. Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 37, 144-155, 2017-01. [JCR]　[WOS]
Wen-Wei Lin, Yuan-Chin Hsieh, Yi-An Cheng, Kuo-Hsiang Chuang, Chien-Chiao Huang, Chih-Hung Chuang, I-Ju Chen, Kai-Wen Cheng, Yun-Chi Lu, Ta-Chun Cheng, Yeng-Tseng Wang, Steve R. Roffler*, and Tian-Lu Cheng*. Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules. ANALYTICAL CHEMISTRY. 88(24), 12371–12379, 2016-12. [JCR]　[WOS]
Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH, Cheng TL. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Scientific reports. 6, 39119, 2016-12. [JCR]　[WOS]
Wu JP, Cheng B, Roffler SR*, Lundy DJ, Yen CY, Chen P, Lai JJ, Pun SH, Stayton PS, Hsieh PC*. Reloadable multidrug capturing delivery system for targeted ischemic disease treatment. Science Translational Medicine. 8(365), 365ra160, 2016-11. [JCR]　[WOS]
Henry CE, Wang YY, Yang Q, Hoang T, Chattopadhyay S, Hoen T, Ensign LM, Nunn KL, Schroeder H, McCallen J, Moench T, Cone R, Roffler SR, Lai SK. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus. Acta biomaterialia. 43, 61-70, 2016-10. [JCR]　[WOS]
Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, Cheng TL, Chen YT, Wu JY, (Roffler SR*). Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Analytical chemistry. 88(21), 10661-10666, 2016-10. [JCR]　[WOS]
Lin WW, Chen IJ, Cheng TC, Tung YC, Chu PY, Chuang CH, Hsieh YC, Huang CC, Wang YT, Kao CH, Roffler SR, Cheng TL. A Secondary Antibody-Detecting Molecular Weight Marker with Mouse and Rabbit IgG Fc Linear Epitopes for Western Blot Analysis. PloS one. 11(8), e0160418, 2016-08. [JCR]　[WOS]
Lin SI, Huang MH, Chang YW, Chen IH, Roffler S, Chen BM, Sher YP, Liu SJ. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice. Cancer letters. 377(2), 126-33, 2016-07. [JCR]　[WOS]
Prijovich ZM, Burnouf PA, Chou HC, Huang PT, Chen KC, Cheng TL, Leu YL, Roffler SR. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. Molecular pharmaceutics. 13(4), 1242-50, 2016-04. [JCR]　[WOS]
Kooijmans SA, Aleza CG, (Roffler SR), van Solinge WW, Vader P, Schiffelers RM. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. Journal of extracellular vesicles. 5, 31053-31053, 2016-03. [JCR]　[WOS]
Sher YP, Lin SI, Chen IH, Liu HY, Lin CY, Chiang IP, Roffler S, Chen HW, Liu SJ. A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model. Oncotarget. 7(1), 671-683, 2016-01. [JCR]　[WOS]
Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK, Cheng TL, (Roffler SR*). Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. ACS nano. 10(1), 648-662, 2016-01. [JCR]　[WOS]
Chuang HY, Suen CS, Hwang MJ, Roffler SR. Toward reducing immunogenicity of enzyme replacement therapy: altering the specificity of human beta-glucuronidase to compensate for alpha-iduronidase deficiency. PROTEIN ENGINEERING DESIGN & SELECTION. 28(11), 519-530, 2015-11. [JCR]　[WOS]
Hsieh YT, Lin HP, Chen BM, Huang PT, Roffler SR. Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity. PloS one. 10(10), e0141088, 2015-10. [JCR]　[WOS]
Tung HY, Su YC, Chen BM, Burnouf PA, Huang WC, Chuang KH, Yan YT, Cheng TL, Roffler SR. Selective Delivery of PEGylated Compounds to Tumor Cells by anti-PEG Hybrid Antibodies. Molecular cancer therapeutics. 14(6), 1317-1326, 2015-04. [JCR]　[WOS]
Cheng TC, Chuang KH, Roffler SR, Cheng KW, Leu YL, Chuang CH, Huang CC, Kao CH, Hsieh YC, Chang LS, Cheng TL, Chen CS. Discovery of Specific Inhibitors for Intestinal E. coli beta-Glucuronidase through In Silico Virtual Screening. TheScientificWorldJournal. 2015, 740815, 2015-03. [JCR]
Mousavi MZ, Chen HY, Hou HS, Chang CY, Roffler S, Wei PK, Cheng JY. Label-free detection of rare cell in human blood using gold nano slit surface plasmon resonance. BIOSENSORS. 5(1), 98-117, 2015-03. [JCR]　[WOS]
M Richter, R Yumul, H Wang, K Saydaminova, M Ho, D May, A Baldessari, M Gough, C Drescher, N Urban, S Roffler, C Zubieta, D Carter, P Fender, A Lieber. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. MOLECULAR THERAPY. 2,15005, 2015-03. [JCR]　[WOS]
Hsieh YT, Chen KC, Cheng CM, Cheng TL, Tao MH, Roffler SR. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy. PloS one. 10(2), e0118028, 2015-02. [JCR]　[WOS]
Lin YC, Roffler SR, Yan YT, Yang RB. Disruption of Scube2 impairs endochondral bone formation. JOURNAL OF BONE AND MINERAL RESEARCH. 30(7), 1255-1267, 2015-01. [JCR]　[WOS]
Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials. 35(37), 9930-9940, 2014-12. [JCR]　[WOS]
Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL. PET Imaging of beta-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy. Molecular Cancer Therapeutics. 13(12), 2852-2863, 2014-12. [JCR]　[WOS]
Chuang KH, Hsieh YC, Chiang IS, Chuang CH, Kao CH, Cheng TC, Wang YT, Lin WW, Chen BM, Roffler SR, Huang MY, Cheng TL. High-throughput sorting of the highest producing cell via a transiently protein-anchored system. PloS one. 9(7), e102569, 2014-07. [JCR]　[WOS]
Su YC, Al-Qaisi TS, Tung HY, Cheng TL, Chuang KH, Chen BM, (Roffler SR*). Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies. mAbs. 6(4), 1069-1083, 2014-07. [JCR]　[WOS]
Wu MY, Lin YC, Liao WJ, Tu CF, Chen MH, Roffler SR, Yang RB. Inhibition of the Plasma SCUBE1, a Novel Platelet Adhesive Protein, Protects Mice Against Thrombosis. Arteriosclerosis Thrombosis and vascular Biology. 34(7), 1390-1398, 2014-05. [JCR]　[WOS]
Mousavi MZ, Chen HY, Hou HS, Chang CY, Roffler S, Wei PK, Cheng JY. Label-free detection of rare cell in human blood using gold nano slit surface plasmon resonance. Biosensors. 5(1), 98-117, 2014-03. [JCR]
Lai C, Wu PJ, Roffler SR, Lee ST, Hwang SM, Wang SS, Wang K, Hsieh PC. Clearance Kinetics of Biomaterials Affects Stem Cell Retention and Therapeutic Efficacy. Biomacromolecules. 15(2), 564-573, 2014-02. [JCR]　[WOS]
Prijovich ZM, Burnouf PA, Roffler SR. Versatile on-line SPE HPLC method for the analysis of Irinotecan and its clinically relevant metabolites in biomaterials. Journal of separation science. 37(4), 360-367, 2014-02. [JCR]　[WOS]
KH Chuang, CH Kao, SR Roffler, SJ Lu, TC Cheng, YM Wang, CH Chuang, YC Hsieh, YT Wang, JY Wang, KY Weng, and TL Cheng. Development of an anti-methoxy poly(ethylene glycol) (α-mPEG) cell-based capture system to measure mPEG and mPEGylated molecules. Macromolecules. 47, 6880-6888, 2014. [JCR]　[WOS]
Lin YC, Chen BM, Lu WC, Su CI, Prijovich ZM, Chung WC, Wu PY, Chen KC, Lee IC, Juan TY, Roffler SR. The B7-1 cytoplasmic tail enhances intracellular transport and mammalian cell surface display of chimeric proteins in the absence of a linear ER export motif. PloS one. 8(9), e75084, 2013-09. [JCR]　[WOS]
Chan DV, Sharma R, Ju CY, Roffler SR, Ju ST. A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer. Journal of biomedical science. 20, 16, 2013. [JCR]　[WOS]
Cheng CM, Chen FM, Lu YL, Tzou SC, Wang JY, Kao CH, Liao KW, Cheng TC, Chuang CH, Chen BM, Roffler S, Cheng TL. Expression of beta-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. Cancer gene therapy. 20(5), 276-281, 2013. [JCR]　[WOS]
Chen KC, Schmuck K, Tietze LF, Roffler SR. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Molecular pharmaceutics. 10(5), 1773-1782, 2013. [JCR]　[WOS]
Cheng TC, Chuang KH, Chen M, Wang HE, Tzou SC, Su YC, Chuang CH, Kao CH, Chen BM, Chang LS, Roffler SR, Cheng TL. Sensitivity of PEGylated Interferon Detection by Anti-Polyethylene Glycol (PEG) Antibodies Depends on PEG Length. Bioconjugate chemistry. 24(8), 1408-1413, 2013. [JCR]　[WOS]
Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. JOURNAL OF IMMUNOTHERAPY. 35(3), 235-244, 2012. [JCR]　[WOS]
Kao CH, Cheng CM, Chuang KH, Chuang CH, Tzou SC, Cheng TC, Hsieh YC, Liao KW, Wang YM, Chang LS, Roffler SR, Chen FM, Cheng TL. A regularly spaced and self-revealing protein ladder for anti-tag Western blot analysis. Analytical Biochemistry. 431(1), 1-3, 2012. [JCR]　[WOS]
Cheng TC, Roffler SR, Tzou SC, Chuang KH, Su YC, Chuang CH, Kao CH, Chen CS, Harn IH, Liu KY, Cheng TL, Leu YL. An activity-based near-infrared glucuronide trapping probe for imaging beta-glucuronidase expression in deep tissues. Journal of the American Chemical Society. 134(6), 3103-3110, 2012. [JCR]　[WOS]
Cheng TL, Chuang KH, Chen BM, Roffler SR. Analytical Measurement of PEGylated Molecules. Bioconjugate Chemistry. 23(5), 881-899, 2012. [JCR]　[WOS]
Pan WY, Lo CH, Chen CC, Wu PY, Roffler SR, Shyue SK, Tao MH. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. MOLECULAR THERAPY. 20(5), 927-937, 2012. [JCR]　[WOS]
Beyer I, Cao H, Persson J, Song H, Richter M, Feng Q, Yumul R, van Rensburg R, Li Z, Berenson R, Carter D, Roffler S, Drescher C, Lieber A. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(12), 3340-3351, 2012. [JCR]　[WOS]
Chen CP, Hsieh YT, Prijovich ZM, Chuang HY, Chen KC, Lu WC, Tseng Q, Leu YL, Cheng TL, Roffler SR. ECSTASY, an adjustable membrane-tethered/soluble protein expression system for the directed evolution of mammalian proteins. PROTEIN ENGINEERING DESIGN & SELECTION. 25(7), 367-375, 2012. [JCR]　[WOS]
Chuang CH, Chuang KH, Wang HE, Roffler SR, Shiea JT, Tzou SC, Cheng TC, Kao CH, Wu SY, Tseng WL, Cheng CM, Hou MF, Wang JM, Cheng TL. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate. CLINICAL CANCER RESEARCH. 18(1), 238-247, 2012. [JCR]　[WOS]
Chen KC, Wu SY, Leu YL, Prijovich ZM, Chen BM, Wang HE, Cheng TL, Roffler SR. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. Bioconjugate chemistry. 22(5), 938-948, 2011. [JCR]　[WOS]
Liu Y, Tuve S, Persson J, Beyer I, Yumul R, Li ZY, Tragoolpua K, Hellstrom KE, Roffler S, Lieber A. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer gene therapy. 18(6), 407-418, 2011. [JCR]　[WOS]
Huang PT, Chen KC, Prijovich ZM, Cheng TL, Leu YL, Roffler SR. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors. Cancer gene therapy. 18(6), 381-389, 2011. [JCR]　[WOS]
Persson J, Beyer I, Yumul R, Li Z, Kiem HP, Roffler S, Lieber A. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. PloS one. 6(7), e22303, 2011. [JCR]　[WOS]
Cheng TL, Chuang CH, Chuang KH, Wang HE, Roffler SR, Shiea JT, Tzou SC, Wu SY, Cheng TC, Kao CH, Cheng CM, Tseng WL, Hou MF, Wang JM. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a non-inhibitory protease substrate. CLINICAL CANCER RESEARCH. 18(1), 238-247, 2011. [JCR]　[WOS]
KH Chuang, HE Wang, TC Cheng, SC Tzou, CM Cheng, CH Kao, CH Chuang, WL Tseng, WC Hung, SR Lin, BM Chen, SR Roffler and TL Cheng. Development of an universal anti-polyethylene glycol reporter gene for non-invasive imaging of PEGylated probes. JOURNAL OF NUCLEAR MEDICINE. 51,933-941, 2010-02. [JCR]　[WOS]
Li YC, Chen BM, Wu PC, Cheng TL, Kao LS, Tao MH, Lieber A, Roffler SR. Cutting Edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. JOURNAL OF IMMUNOLOGY. 184(11), 5959-5963, 2010. [JCR]　[WOS]
Chuang KH, Wang HE, Chen FM, Tzou SC, Cheng CM, Chang YC, Tseng WL, Shiea J, Lin SR, Wang JY, Chen BM, Roffler SR, Cheng TL. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. Molecular cancer therapeutics. 9(6), 1903-1912, 2010. [JCR]　[WOS]
Chuang KH, Tzou SC, Cheng TC, Kao CH, Tseng WL, Shiea J, Liao KW, Wang YM, Chang YC, Huang BJ, Wu CJ, Chu PY, Roffler SR, Cheng TL. Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA. Analytical chemistry. 82(6), 2355-2362, 2010. [JCR]　[WOS]
Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. BIOCONJUGATE CHEMISTRY. 21(7), 1264-1270, 2010. [JCR]　[WOS]
Chang CM, Lo CH, Shih YM, Chen Y, Wu PY, Tsuneyama K, Roffler SR, Tao MH. Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Human gene therapy. 21(5), 611-621, 2010. [JCR]　[WOS]
T Jung, D Castellana, P Klingbeil, IC Hernández, M Vitacolonna, DJ Orlicky, (SR Roffler), P Brodt and M Zöller*. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 11, 1093-1105, 2009-11. [JCR]　[WOS]
Tzou SC, Roffler S, Chuang KH, Yeh HP, Kao CH, Su YC, Cheng CM, Tseng WL, Shiea J, Harm IH, Cheng KW, Chen BM, Hwang JJ, Cheng TL, Wang HE. Micro-PET imaging of beta-glucuronidase activity by the hydrophobic conversion of a glucuronide probe. Radiology. 252(3), 754-762, 2009-09. [JCR]　[WOS]
Shieh SJ, Chou FC, Yu PN, Lin WC, Chang DM, (Roffler SR), Sytwu HK. Transgenic expression of single-chain anti-CTLA-4 Fv on beta cells protects nonobese diabetic mice from autoimmune diabetes. Journal of immunology. 183(4), 2277-2285, 2009-08. [JCR]　[WOS]
Juan TY, (Roffler SR*), Hou HS, Huang SM, Chen KC, Leu YL, Prijovich ZM, Yu CP, Wu CC, Sun GH, Cha TL. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity. CLINICAL CANCER RESEARCH. 15(14), 4600-4611, 2009-07. [JCR]　[WOS]
Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY, Strauss R, Hellstrom KE, Disis ML, (Roffler S), Lieber A. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine. 27(31), 4225-4239, 2009-06. [JCR]　[WOS]
ZM Prijovich, KC Chen, (SR Roffler*). Local enzymatic hydrolysis of an endogenously-generated metabolite can enhance CPT-11 anti-cancer efficacy . Molecular Cancer Research. 8(4), 940-946, 2009-04. [JCR]　[WOS]
CH Lee, YH Chiang, SE Chang, CL Chong, BM Cheng and (SR Roffler*). Tumor-localized ligation of CD3 and CD28 with systemic regulatory T cell depletion induces potent innate and adaptive antitumor responses. Clinical Cancer Research. 15,2756-2766, 2009-04. [JCR]　[WOS]
CM Cheng, PY Chu, KH Chuang, (SR Roffler), CH Kao, WL Tseng, J Shiea, WD Chang, YC Su, BM Chen, YM Wang and TL Cheng*. Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems. Cancer Gene Therapy. 16, 83-90, 2009-01. [JCR]　[WOS]
KC Chen, CH Wu, CY Chang, WC Lu, Q Tseng, ZM Prijovich, W Schechinger, YC Liaw, YL Leu, (Roffler SR*). Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display. Chemistry & Biology. 15, 1277-1286, 2008-12. [JCR]　[WOS]
H. Wang, Y. Liu, Z. Li, S. Tuve, D. Stone, O. Kalyushniy, D. Shayakhmetov, C. L. Verlinde, T. Stehle, J. McVey, A. Baker, K. W. Peng, (S. Roffler) and A. Lieber*. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. Journal of Virology. 82, 10567-10579, 2008-11. [JCR]　[WOS]
T. L. Cheng and (S. R. Roffler*). Membrane-tethered proteins for basic research, imaging and therapy. Medicinal Research Reviews. 28, 885-928, 2008-11. [JCR]　[WOS]
K. H. Chuang, W. C. Hung, J. Shiea, Y. C. Su, C. H. Kao, B. M. Chen, (S. R. Roffler*) and Tian-Lu Cheng*. Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Therapy. 15, 393-401, 2008-06. [JCR]　[WOS]
H. Wang, Y. C. Liaw, D. Stone, O. Kalyuzhniy, I. Amiraslanov, S. Tuve, C. L. Verlinde, D. Shayakhmetov, T. Stehle, (S. Roffler) and A. Lieber*. Identification of CD46 Binding Sites within the Adenovirus Serotype 35 Fiber Knob. J Virol. 81, 12785-12792, 2007-12. [JCR]　[WOS]
P. Volna, J. Jarjour, S. Baxter, (S. R. Roffler), R. J. Jr. Monnat, B. L. Stoddard and A. M. Scharenberg*. Flow cytometric analysis of DNA binding and cleavage by cell surface-displayed homing endonucleases. Nucleic Acids Research. 35(8), 2748-2758, 2007-08. [JCR]　[WOS]
S. Tuves, B. M. Chen, Y. Liu, T. L. Cheng, P. Toure, P. S. Sow, Q. Feng, N. Kiviat, R. Strauss, S. Ni, Z. Y. Li, (S. R. Roffler*) and A. Lieber*. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor destructive immune responses. Cancer Research. 67(12), 5929-5939, 2007-06. [JCR]　[WOS]
Z. M. Prijovich, Y. L. Leu and (S. R. Roffler*). Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother Pharmacol. 60, 7-17, 2007-06. [JCR]　[WOS]
Y. C. Su, K. H. Chuang, Y. M. Wang, C. M. Cheng, S. R. Lin, J. Y. Wang, J. J. Hwang, B. M. Chen, K. C. Chen, (S. R. Roffler*) and T. L. Cheng*. Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. Gene Ther. 14(7), 565-574, 2007-04. [JCR]　[WOS]
K. C. Chen, T. L. Cheng, Y. L. Leu, Z. M. Prijovich, C. H. Chuang, B. M. Chen and (S. R. Roffler*). Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther. 14(2), 187-200, 2007-02. [JCR]　[WOS]
AB Liu* and (SR Roffler). Anti-CTLA-4 scFv, a single-chain antibody, protects the expression of E. coli beta-galactosidase during repeated intramuscular injections in immune-competent mice. Tzu Chi Med J. 18, 259-265, 2006-06. [JCR]
K. H. Chuang, C. M. Cheng, (S. R. Roffler), Y. L. Lu, S. R. Lin, J. J. Wang, W. S. Tzou, Y. C. Su, B. M. Chen and T. L. Cheng*. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjugate Chem. 17, 707-714, 2006-05. [JCR]　[WOS]
(S. R. Roffler), H. E. Wang, H. M. Yu, W. D. Chang, C. M. Cheng, Y. L. Lu, B. M. Chen and T. L. Cheng*. A membrane antibody receptor for noninvasive imaging of gene expression. Gene Ther. 13, 412-420, 2006-03. [JCR]　[WOS]
D. Kiewlich, J. Zhang, C. Cross, W. Xia, B. Larsen, R. R. Cobb, S. Biroc, J. M. Gu, T. Sato, D. R. Ligh, T. Heitner, J. Willuda, D. Vogel, F. Monteclaro, A. Citkowicz, (S. R. Roffler) and D. A. Zajchowski*. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia. 8(1), 18-30, 2006-01. [JCR]　[WOS]
Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, Lin YH, (Roffler SR*). Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjugate Chemistry. 16, 1225-1231, 2005-09. [JCR]　[WOS]
Y. W. Chang, S. C. Chen, E. C. Cheng, Y. P. Ko, Y. R. Kao, Y. C. Tsai, S. Y. Chen, Y. G. Tsay, P. C. Yang, C. W. Wu and (S. R. Roffler*). CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int J Cancer. 116, 243-252, 2005-08. [JCR]　[WOS]
MH Yu*, (SR Roffler) and BM Chen. Topoisomerase I activity in ovarian cancer is a predictor of sensitivity to topotecan chemotherapy. Taiwan Gynecol Oncol. 2, 14-22, 2005-05. [JCR]
Y. P. Sher, J. Y. Shih, P. C. Yang, (S. R. Roffler), Y. W. Chu, C. W. Wu, C. L. Yu and K. Peck*. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res. 11, 173-179, 2005-01. [JCR]　[WOS]
C. J. Chang, K. F. Tai, (S. R. Roffler) and L. H. Hwang*. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol. 173, 6025-6032, 2004-12. [JCR]　[WOS]
C. H. Wu, W. R. Balasubramanian, Y. P. Ko, G. Hsu, S. E. Chang, Z. M. Prijovich, K. C. Chen and (S. R. Roffler*). A simple method for the production of recombinant proteins from mammalian cells. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY. 40, 167-172, 2004-10. [JCR]　[WOS]
T. L. Cheng, K. W. Liao, S. C. Tzou, C. M. Cheng, B. M. Chen and (S. R. Roffler*). Hapten-directed targeting to single-chain antibody receptors. Cancer Gene Ther. 11, 380-388, 2004-05. [JCR]　[WOS]
F. H. Chang, C. H. Lee, M. T. Chen, C. C. Kuo, Y. L. Chiang, C. Y. Hang and (S. R. Roffler). Surfection: a new platform for transfected cell arrays. Nucleic Acids Res. 32, e33, 2004-02. [JCR]　[WOS]
A. B. Liu*, (S. R. Roffler). Anti-CTLA4 scFv, a single-chain antibody, can prolong expression of Escherichia. coli. beta- galactosidase in immune-competent mice. Tzu Chi Med J. 16, 25-31, 2004-01. [JCR]
S. R. Roffler, K. W. Liao. Chimeric protein and method of controlling tumor growth using the protein. US Patent. 6,699,972, 2004.
H. K. Sytwu*, W. D. Lin, (S. R. Roffler), J. T. Hung, H. S. Sung, C. H. Wang, T. L. Cheng, S. C. Tsou, S. C. Hsi and K. L. Shen. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun. 21, 247-254, 2003-11. [JCR]　[WOS]
Z. M. Prijovich, Y. L. Leu and (S. R. Roffler*). Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem Pharmacol. 66, 1181-1187, 2003-10. [JCR]　[WOS]
K. W. Liao, B. M. Chen, T. B. Liu, S. C. Tzou, Y. M. Lin, K. F. Lin, C. I. Su and (S. R. Roffler*). Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Cancer Gene Ther. 10, 779-790, 2003-10. [JCR]　[WOS]
C. H. Lo, S. C. Lee, P. Y. Wu, W. Y. Pan, J. Su, C. W. Cheng, (S. R. Roffler), B. L. Chiang, C. N. Lee, C. W. Wu and M. H. Tao*. Antitumor and antimetastatic activity of IL-23. J Immunol. 171, 600-607, 2003-07. [JCR]　[WOS]
Y. R. Kao, J. Y. Shih, W. C. Wen, Y. P. Ko, B. M. Chen, Y. L. Chan, Y. W. Chu, P. C. Yang, C. W. Wu and (S. R. Roffler*). Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res. 9, 2807-2816, 2003-07. [JCR]　[WOS]
N. M. Tsai, B. M. Chen, S. L. Wei, C. W. Wu and (S. R. Roffler*). Anti-tumor immunoglobulin M increases lung metastasis in an experimental model of malignant melanoma. Clin Exp Metastasis. 20, 103-109, 2003-03. [JCR]　[WOS]
S. R. Roffler, T. L. Cheng and P. Y. Wu. Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol- modified molecules. US Patent. 6,596,849, 2003.
S. R. Roffler, J. W. Chern and Y. L. Leu. Proactive antitumor compounds. European Patent. EP0990661, 2003.
K. M. Bernt, D. S. Steinwaerder, S. Ni, Z. Y. Li, (S. R. Roffler) and A. Lieber*. Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res. 62, 6089-6098, 2002-11. [JCR]　[WOS]
Z. M. Prijovich, B. M. Chen, Y. L. Leu, J. W. Chern and (S. R. Roffler*). Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. British Journal of Cancer. 86, 1634-1638, 2002-05. [JCR]　[WOS]
B. M. Chen, T. L. Cheng, S. C. Tzou and (S. R. Roffler*). Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int J Cancer. 94, 850-858, 2001-12. [JCR]　[WOS]
J. J. Chen, K. Peck, T. M. Hong, S. C. Yang, Y. P. Sher, J. Y. Shih, R. Wu, J. L. Cheng, (S. R. Roffler), C. W. Wu and P. C. Yang. Global analysis of gene expression in invasion by a lung cancer model. Cancer Research. 61, 5223-5230, 2001-07. [JCR]　[WOS]
K. W. Liao, W. C. Chou, Y. C. Lo and (S. R. Roffler*). Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnology and Bioengineering. 73, 313-323, 2001-05. [JCR]　[WOS]
N. M. Tsai, T. L. Cheng and (S. R. Roffler*). Sensitive measurement of polyethylene glycol-modified proteins. Biotechniques. 30, 396-402, 2001-02. [JCR]　[WOS]
B. M. Chen, J. Y. Chen, M. Kao, J. B. Lin, M. H. Yu and (S. R. Roffler*). Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy. Gynecol Oncol. 79, 272-280, 2000-11. [JCR]　[WOS]
K. W. Liao, Y. W. Chang and (S. R. Roffler*). Presence of cloning vector sequences in the untranslated region of some genes in Genbank. J Biomed Sci. 7, 529-530, 2000-11. [JCR]　[WOS]
C. L. Hou, C. Tang, (S. R. Roffler) and T. K. Tang*. Protein 4.1R binding to eIF3-p44 suggests an interaction between the cytoskeletal network and the translation apparatus. Blood. 96, 747-753, 2000-07. [JCR]　[WOS]
S. C. Lin, (S. R. Roffler), T. L. Cheng, K. T. Chang and J. P. Chang and J. J. Wang*. Characterization of a tumor-specific antigen expressing on Chang hepatoma ascites cells. Acta Histochemica et Cytochemica. 33, 367-375, 2000-05. [JCR]　[WOS]
T. L. Cheng, B. M. Chen, J. W. Chern, M. F. Wu and (S. R. Roffler*). Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjugate Chemistry. 11, 258-266, 2000-03. [JCR]　[WOS]
K. W. Liao, Y. C. Lo and (S. R. Roffler*). Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. 7, 339-347, 2000-02. [JCR]　[WOS]
S. R. Roffler, J. W. Chern and Y. L. Leu. Proactive antitumor compounds. US Patent. #6,043,367, 2000.
W. C. Chou, K. W. Liao, Y. C. Lo, S. Y. Jiang, M. Y. Yeh and (S. R. Roffler). Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng. 65, 160-169, 1999-10. [JCR]　[WOS]
A. Y. Shen*, C. P. Chen and (S. Roffler). A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethyl-8-hydroxyquinoline. Life Sci. 64, 813-825, 1999-09. [JCR]　[WOS]
Y. L. Leu, (S. R. Roffler*) and J. W. Chern*. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem. 42, 3623-3628, 1999-09. [JCR]　[WOS]
J. W. Lomasney, H. F. Cheng, (S. R. Roffler) and K. King*. Activation of phospholipase C delta1 through C2 domain by a Ca(2+)-enzyme-phosphatidylserine ternary complex. J Biol Chem. 274, 21995-22001, 1999-07. [JCR]　[WOS]
T. L. Cheng, W. C. Chou, B. M. Chen, J. W. Chern and (S. R. Roffler*). Characterization of an antineoplastic glucuronide prodrug. Biochem Pharmacol. 58, 325-328, 1999-07. [JCR]　[WOS]
T. L. Cheng, P. Y. Wu, M. F. Wu, J. W. Chern and (S. R. Roffler*). Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjugate Chemistry. 10, 520-528, 1999-05. [JCR]　[WOS]
T. L. Cheng, S. L. Wei, B. M. Chen, J. W. Chern, M. F. Wu, P. W. Liu and (S. R. Roffler*). Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. British Journal of Cancer. 79, 1378-1385, 1999-03. [JCR]　[WOS]
K. Peck, Y. P. Sher, J. Y. Shih, (S. R. Roffler), C. W. Wu and P. C. Yang. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 58, 2761-2765, 1998-07. [JCR]　[WOS]
B. M. Chen, L. Y. Chan, S. M. Wang, M. F. Wu, J. W. Chern and (S. R. Roffler*). Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats. Int J Cancer. 73, 392-402, 1997-11. [JCR]　[WOS]
T. L. Cheng, B. M. Chen, L. Y. Chan, P. Y. Wu, J. W. Chern and (S. R. Roffler*). Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother. 44, 305-315, 1997-08. [JCR]　[WOS]
S. Y. Jiang, R. Y. Shyu, M. F. Huang, H. S. Tang, T. H. Young, (S. R. Roffler), Y. S. Chiou and M. Y. Yeh*. Detection of alpha fetoprotein-expressing cells in the blood of patients with hepatoma and hepatitis. British Journal of Cancer. 75, 928-933, 1997-06. [JCR]　[WOS]
A. Y. Shen*, M. H. Hwang, (S. R. Roffler) and C. F. Chen. Cytotoxicity and antimicrobial activity of some naphthol derivatives. Archiv Der Pharmazie. 328, 197-201, 1995-02. [JCR]　[WOS]
R. Y. Shyu, S. Y. Jiang, S. L. Huang, T. C. Chang, K. L. Wu, (S. R. Roffler) and M. Y. Yeh*. Growth regulation by all-trans-retinoic acid and retinoic acid receptor messanger ribonucleic acids expression in gastric cancer cells. Eur J Cancer. 31A, 237-243, 1995. [JCR]　[WOS]
JJ Wang, (SR Roffler) HH Chou, FY Yin, and CS Yin. Characterization of mullerian inhibiting substance binding on cervical carcinoma cells demonstrated by immunohistochemistry. TISSUE & CELL. 26, 467-476, 1994-04. [JCR]　[WOS]
(S. R. Roffler), J. Chan and M. Y. Yeh*. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res. 54, 1276-1285, 1994-03. [JCR]　[WOS]
M. H. Yu, (S. R. Roffler), W. S. Hwang, E. Tung, W. L. Chen and M. Y. Yeh*. Localization and therapy of human cervical tumor xenografts with radiolabeled monoclonal antibody 1H10. Gynecol Oncol. 47, 93-101, 1992-10. [JCR]　[WOS]
S. M. Wang, J. W. Chern, M. Y. Yeh, J. C. Ng, E. Tung and (S. R. Roffler*). Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52, 4484-4491, 1992-08. [JCR]　[WOS]
J. J. Wang, (S. R. Roffler), M. H. Yu, S. H. Chou, C. H. Cheng, C. S. Yin and M. Y. Yeh*. Characterization of a human cervical carcinoma-associated antigen by lectin binding and immuno-electron microscopy . HISTOCHEMISTRY. 97, 453-461, 1992-07. [JCR]　[WOS]
M. Y. Yeh*, (S. R. Roffler) and M. H. Yu. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer. 51, 274-282, 1992-05. [JCR]　[WOS]
(S. R. Roffler*), S. M. Wang, J. W. Chern, M. Y. Yeh and E. Tung. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol. 42, 2062-2065, 1991-11. [JCR]　[WOS]
(S. R. Roffler), M. H. Yu, B. M. Chen, E. Tung and M. Y. Yeh*. Therapy of human cervical carcinoma with monoclonal antibody-Pseudomonas exotoxin conjugates. Cancer Res. 51, 4001-4007, 1991-08. [JCR]　[WOS]
(S. R. Roffler), M. H. Yu, M. R. Chen, S. C. Chen, C. T. Hsu and M. Y. Yeh*. New monoclonal antibody against human cervical carcinoma with diagnostic and therapeutic potential. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 24, 19-29, 1991-02. [JCR]
M. H. Yu, (S. R. Roffler), H. S. Liu, C. S. Yin and M. Y. Yeh*. Flow cytometric analysis of monoclonal antibody reactivity and specificity against human cervical carcinoma. Chinese J Obstet Gynaecol. 30, 90-95, 1991.
S. R. Roffler, T. W. Randolph, D. A. Miller, H. W. Blanch and J. M. Prausnitz. Extractive Fermentation. Extractive Bioconversions. chapter, (space), 1990.
(S. R. Roffler), H. W. Blanch and C. R. Wilke. Design and mathematical description of differential contactors used in extractive fermentation. Biotechnol Bioeng. 32, 192-204, 1988-05. [JCR]　[WOS]
(S. R. Roffler), H. W. Blanch and C. R. Wilke. In-situ extractive fermentation of acetone and butanol. Biotechnol Bioeng. 31, 135-143, 1988-02. [JCR]　[WOS]
(S. R. Roffler), H. W. Blanch and C. R. Wilke. In-situ recovery of butanol during fermentation. I. Batch extractive fermentation. BIOPROCESS ENGINEERING. 2, 1-12, 1987. [JCR]
(S. R. Roffler), H. W. Blanch and C. R. Wilke. In-situ recovery of butanol during fermentation. II. Fed-batch extractive fermentation. BIOPROCESS ENGINEERING. 2, 181-190, 1987. [JCR]　[WOS]
(S. R. Roffler), H. W. Blanch and C. R. Wilke. In-situ recovery of fermentation products. Trends Biotechnol. 2, 129-136, 1984. [JCR]　[WOS]

Book 0